Fifth Third Bancorp
CASC

Fifth Third Bancorp’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Fifth Third Bancorp’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-8
Closed – – 2481
2017
Q4 		$0 Hold
8
– – ﹤0.01% 2418
2017
Q3 		$0 Hold
8
– – ﹤0.01% 2354
2017
Q2 		$0 Hold
8
– – ﹤0.01% 2320
2017
Q1 		$0 Hold
8
– – ﹤0.01% 2280
2016
Q4 		$0 Hold
8
– – ﹤0.01% 2359
2016
Q3 		$0 Hold
8
– – ﹤0.01% 2366
2016
Q2 		$0 Hold
8
– – ﹤0.01% 2410
2016
Q1 		$0 Hold
8
– – ﹤0.01% 2847
2015
Q4 		$0 Hold
8
– – ﹤0.01% 2982
2015
Q3 		$0 Hold
8
– – ﹤0.01% 3085
2015
Q2 		$0 Buy
+8
New +$127 ﹤0.01% 2969

Fifth Third Bancorp's CASC Position: Q1 2018 in Review

Fifth Third Bancorp sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 8 shares.

Fifth Third Bancorp first reported a position in CASC in Q2 2015 and held it in 11 quarters. The position peaked at $0 in Q4 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

  • Fifth Third Bancorp reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Fifth Third Bancorp sold 8 Cascadian Therapeutics, Inc. shares in Q1 2018.
  • Fifth Third Bancorp first reported a position in Cascadian Therapeutics, Inc. in Q2 2015 and held it in 11 quarters.
  • Fifth Third Bancorp's Cascadian Therapeutics, Inc. position peaked at $0 in Q4 2017.
  • 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Fifth Third Bancorp's 13F filing for Q1 2018, filed 15 May 2018.